focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDNL.L Share News (DNL)

  • There is currently no data for DNL

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AIM WINNERS & LOSERS: Diurnal shares more than double on takeover bid

Tue, 30th Aug 2022 11:04

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Tuesday.

----------

AIM - WINNERS

----------

Diurnal Group PLC, shares surge to 26.19 pence from Friday's close of 11.25p, 12-month range 9.5-67.9p. The pharmaceutical company focused on hormonal diseases agrees to be taken over by Neurocrine Biosciences Inc in deal worth GBP48.3 million. Neurocrine is offering 27.5p, cash, for each Diurnal share. Diurnal directors unanimously recommend deal. "We believe that the acquisition is compelling for Diurnal's shareholders given the risks associated with achieving Diurnal's vision of creating a profitable business, in particular the ongoing commercial roll out of Diurnal's products in Europe and the execution of key clinical studies, in addition to the substantial shareholder dilution that is likely to result from accessing the capital required to deliver this vision," says Non-Executive Chair Anders Harfstrand.

----------

SIMEC Atlantis Energy Ltd, up 31% at 2.03p, 12-month range 0.97p-5.3p. The sustainable energy generation firm secures necessary grid variations for the 230 megawatt/460 megawatt hour battery energy storage system at the Uskmouth site and has completed the novation of the grid connection agreement. "With excellent progress being made, the project is on track to be operational by 2024," it says. Adds it now has no loans outstanding with any SIMEC group company.

----------

MyCelx Technologies Corp, up 14% at 48.36p, 12-month range 30.55p-92.00p. The clean water and air technology firm secures new purchase order from SABIC Agri-Nutrients, a SABIC affiliate, to provide clean water for optimal performance in their fertiliser production process. Also wins short-term emergency response project with a independent petrochemical company in Saudi Arabia and secures renewal of two water treatment contracts with long-standing customers in the Middle East. "These projects underpin the 2022 revenue forecast, and the company remains on track to meet current guidance," it says.

----------

AIM - LOSERS

----------

Petroneft Resources PLC, down 28% at 0.645p, 12-month range 0.65p-4.88p. Reports temporary suspension of oil acceptance and transfer from Licence 61 by Nord Imperial LLC. In 2009, contract was signed with Nord Imperial to cover storage and transfer of oil by pipeline from Licence 61 to the Transneft Entry point at Zavyalovo. Petroneft says it has considered contract tariff to be "significantly higher than normal market rates" for some time. Says payments were made to Nord Imperial at reduced levels amid no progress in finding "more equitable" outcome and, in response, Nord Imperial has temporarily suspending the acceptance of oil and transfer. "As the company currently have no other export route from Licence 61, Petroneft is progressively shutting down its wells until the situation can be resolved," it says.

----------

Joules Group PLC, down 7.5% at 23.58p, 12-month range 19.41p-257.00p. Retailer insists it continues in "positive" discussions with Next over a possible investment, despite Sky News over the weekend reporting that talks had stalled. Sky News said it has learnt the two companies are not close to agreeing the terms of an investment from Next, and the FTSE 100-listed retailer had not received enough financial information to allow it to make a formal offer to the Joules board. There were also doubts that Next would want to proceed with a deal at 33p per share or more given Joules shares closed at 25.5p on Friday. The stock has fallen 82% since the start of 2022, and shares had closed at 33p the day before the companies confirmed they were in talks over the potential equity investment.

----------

By Lucy Heming; lucyheming@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

More News
10 Jan 2019 11:33

Diurnal Shares Surge As Secures Second Patent For Chronocort In US

LONDON (Alliance News) - Diurnal Group PLC on Thursday said the US Patent & Trademark Office has granted the company a second US patent for Chronocort.Diurnal shares almost tripled on a

Read more
10 Jan 2019 11:26

Diurnal awarded US patent for Chronocort product

(Sharecast News) - Specialty pharmaceutical company Diurnal Group announced on Thursday that the US Patent and Trademark Office (USPTO) has granted a second US patent for its 'Chronocort' modified release hydrocortisone product.

Read more
17 Oct 2018 12:10

Diurnal halts US development of Chronocort after European trials come up short

(Sharecast News) - Speciality pharmaceutical company Diurnal has put all development activities for its modified release hydrocortisone product on hold after it failed to meet its primary endpoint in a recent phase-three European trial.

Read more
17 Oct 2018 10:41

Diurnal Puts All Chronocort US Development Activities On Hold

LONDON (Alliance News) - Diurnal Group PLC said Wednesday it decided to put all US development activities for its Chronocort product on hold, after it failed to meet its primary objective in its a

Read more
8 Oct 2018 17:07

LONDON MARKET CLOSE: Stocks End Lower On Chinese And Italian Woes

LONDON (Alliance News) - Stocks closed lower Monday on the actions of the Chinese and Italian governments, as the pound continued its fall on news from 10 Downing Street there remains "big in of

Read more
8 Oct 2018 15:15

Diurnal Group Child Adrenal Insufficiency Drug Approved In Scotland

LONDON (Alliance News) - Diurnal Group PLC said Monday the Scottish Medicines Consortium approved the routine use of Alkindi, a first-line treatment of young children with adrenal insufficiency to

Read more
8 Oct 2018 12:00

LONDON MARKET MIDDAY: China Prompts Sell-Off In Europe; Insurers Fall

LONDON (Alliance News) - Share prices in London had slipped firmly into the red by midday on Monday following a slump in Chinese equities overnight."Europe is following the Asian lead, with a 3%

Read more
8 Oct 2018 10:33

WINNERS & LOSERS SUMMARY: French Connection In Vogue On Possible Sale

LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Monday.----------FTSE 100 - up 1.0%. The asset manager confirmed it is in to

Read more
8 Oct 2018 09:29

Diurnal's endocrine drug does not meet trial objective

(Sharecast News) - Clinical trials of Diurnal Group's Chronocort drug failed to meet the primary objective of proving superior to conventional therapy in endocrine control over a 24-hour period.

Read more
8 Oct 2018 08:54

Shares In IP Group, Diurnal Suffer After Chronocort Trial Disappoints

LONDON (Alliance News) - Diurnal Group PLC said Monday its phase-three European trial of Chronocort did not meet its primary objective, causing shares in the pharmaceutical company to property IP

Read more
8 Oct 2018 07:48

LONDON MARKET PRE-OPEN: Lower Call; Schroders Confirms Lloyds Talks

LONDON (Alliance News) - Stocks in London on Monday are set to continue last week's slide, fuelled by concerns that strong US economic data will lead to a quickened pace of interest rate hikes.In

Read more
5 Oct 2018 09:20

Diurnal kicks off adrenal condition trial with first patients

(Sharecast News) - Specialist pharmaceutical company Diurnal said it had enrolled the first two patients in its US-based Chronocort phase III trial for adults with congenital adrenal hyperplasia (CAH).

Read more
5 Oct 2018 08:16

Diurnal Enrols First Patients In Phase Three US Chronocort Trial

LONDON (Alliance News) - Pharmaceutical company Diurnal Group PLC on Friday said the first two patients have been enrolled into its phase three US trial of Chronocort.Chronocort is a form a

Read more
20 Sep 2018 09:56

Diurnal Generates First Revenue But Loss Deepens As Costs Rise

LONDON (Alliance News) - Pharmaceutical firm Diurnal Group PLC said Thursday its annual loss deepened amid higher costs despite generating its first revenue from drug sales.For the year the

Read more
15 Aug 2018 12:39

German Body Says Diurnal Alkindi's Benefit Over Generic Not Proven

LONDON (Alliance News) - Diurnal Group PLC said Wednesday a German body published a study which says that the benefit of the company's product Alkindi over generic hydrocortisone has not been

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.